ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is among the fastest growing small cap stocks to buy. Lupin Inc., a leading player in the healthcare sector, sent a Paragraph IV certification notice to ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on August 13, 2025, outlining that Lupin has submitted an Abbreviated New Drug Application (ANDA) to the FDA for approval of the launch of a generic version of ARS’s neffy© nasal spray before multiple patents expire.

In response, ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is working to aggressively defend its patents through the filing of a patent infringement lawsuit against Lupin, which could delay the FDA approval of Lupin’s generic product by 30 months if filed within the next 45 days. Although the outcome remains uncertain, one thing is certain: this would substantially impact the company’s market leadership and intellectual property rights.

Neffy is considered a blockbuster for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) for emergency allergic reactions. While much of the company’s prospects depend on its market position and Neffy’s market demand, the outlook remains quite encouraging.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), headquartered in San Diego, California, is a biopharmaceutical company providing treatments for severe allergic reactions. Founded in 2015, the company is committed to offering patient-friendly solutions.

While we acknowledge the potential of SPRY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.